Teachers Advisors LLC increased its position in shares of WAVE Life Sciences Ltd. (NASDAQ:WVE) by 64.5% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 21,534 shares of the company’s stock after acquiring an additional 8,446 shares during the period. Teachers Advisors LLC owned about 0.08% of WAVE Life Sciences worth $401,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of WVE. Bank of New York Mellon Corp lifted its holdings in WAVE Life Sciences by 0.9% during the 1st quarter. Bank of New York Mellon Corp now owns 31,350 shares of the company’s stock worth $862,000 after buying an additional 279 shares during the period. American International Group Inc. lifted its holdings in WAVE Life Sciences by 7.1% during the 1st quarter. American International Group Inc. now owns 4,554 shares of the company’s stock worth $125,000 after buying an additional 302 shares during the period. Strs Ohio lifted its holdings in WAVE Life Sciences by 6.3% during the 2nd quarter. Strs Ohio now owns 11,900 shares of the company’s stock worth $221,000 after buying an additional 700 shares during the period. Schwab Charles Investment Management Inc. lifted its holdings in WAVE Life Sciences by 6.5% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 30,707 shares of the company’s stock worth $845,000 after buying an additional 1,881 shares during the period. Finally, Geode Capital Management LLC lifted its holdings in WAVE Life Sciences by 4.6% during the 1st quarter. Geode Capital Management LLC now owns 76,478 shares of the company’s stock worth $2,103,000 after buying an additional 3,397 shares during the period. Institutional investors and hedge funds own 69.53% of the company’s stock.

WVE has been the topic of a number of recent analyst reports. Mizuho set a $34.00 price objective on WAVE Life Sciences and gave the company a “buy” rating in a research note on Friday, August 18th. BidaskClub raised WAVE Life Sciences from a “sell” rating to a “hold” rating in a research note on Saturday, August 26th. Jefferies Group LLC reissued a “buy” rating and issued a $40.00 price objective (down from $42.00) on shares of WAVE Life Sciences in a research note on Thursday, August 10th. Finally, Zacks Investment Research raised WAVE Life Sciences from a “sell” rating to a “hold” rating in a research note on Thursday, October 12th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $38.75.

COPYRIGHT VIOLATION NOTICE: This news story was first posted by Watch List News and is owned by of Watch List News. If you are reading this news story on another site, it was illegally stolen and reposted in violation of United States and international copyright laws. The legal version of this news story can be read at https://www.watchlistnews.com/teachers-advisors-llc-raises-position-in-wave-life-sciences-ltd-wve/1703927.html.

WAVE Life Sciences Ltd. (NASDAQ:WVE) opened at $24.75 on Wednesday. The company has a current ratio of 11.50, a quick ratio of 11.50 and a debt-to-equity ratio of 0.01. WAVE Life Sciences Ltd. has a 52 week low of $15.15 and a 52 week high of $40.15.

WAVE Life Sciences (NASDAQ:WVE) last announced its quarterly earnings data on Thursday, November 9th. The company reported ($0.94) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.97) by $0.03. The company had revenue of $0.68 million for the quarter, compared to the consensus estimate of $0.77 million. WAVE Life Sciences had a negative return on equity of 59.52% and a negative net margin of 3,338.68%. research analysts anticipate that WAVE Life Sciences Ltd. will post -3.75 EPS for the current year.

In related news, Director Masaharu Tanaka sold 20,747 shares of the business’s stock in a transaction dated Monday, September 18th. The stock was sold at an average price of $24.21, for a total value of $502,284.87. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 53.00% of the stock is owned by insiders.

WAVE Life Sciences Profile

WAVE Life Sciences Ltd. is a genetic medicines company. The Company, through its synthetic chemistry drug development platform, designs, develops and commercializes a pipeline of nucleic acid therapeutic candidates for genetically defined diseases. The Company is engaged in developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins.

Institutional Ownership by Quarter for WAVE Life Sciences (NASDAQ:WVE)

Receive News & Ratings for WAVE Life Sciences Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for WAVE Life Sciences Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.